Rober McNeil Ph D

Robert McNeil, Ph.D.

Sanderling Ventures

Robert McNeil has over twenty-seven years experience as an active investor and management participant in seed and early-stage biomedical companies. He founded Sanderling Ventures in 1979 and has served since then as a Managing Director of Sanderling’s six investment partnerships.
Dr. McNeil was the seed investor for Western Technology Ventures, Advanced Cardiovascular Systems (acquired by Guidant Corp.) and Ventitrex (acquired by St. Jude Medical). Dr. McNeil was a founder, Chief Executive Officer and Chairman of Stereotaxis, the Chief Executive Officer and Chairman of ReGen Biologics, and the Chairman of Ista Pharmaceuticals, as well as other entities.
As an active investor, Dr. McNeil has been instrumental in the development of InfraReDx, Athenagen/Zapaq and GeminX. In each case, close relationships with management and careful understanding of the companies’ technologies have allowed successful development of products at very early stage.
Dr. McNeil earned his Ph.D. in the fields of molecular biology, biochemistry and genetics in 1972 from the University of California, Irvine.

 

Tim Wollaeger

Tim Wollaeger

Sanderling Ventures

Tim has nearly thirty years’ experience in the medical products and biotechnology fields in both corporate management and venture capital. Mr. Wollaeger joined Sanderling as a Managing Director in 2002, as head of the firm’s San Diego office.
Mr. Wollaeger began his career at Baxter International where his last position was Vice President and General Manager of the Company’s operations in Mexico. In 1983 he joined Hybritech, Inc., San Diego’s first biotechnology company, as Vice President and Chief Financial Officer. Following Hybritech’s acquisition by Eli Lilly & Co in 1986, he became a founding General Partner of Biovest, a San Diego based venture capital firm. At Biovest, he helped found and remained an active Board member in Pyxis, Vical and Biosite. All three of these companies became public and Pyxis was acquired by Cardinal Health in 1996 for a $1 billion.
He then helped found Columbia Hospital Corporation in 1990 and was a Senior Vice President and member of the Board of Directors until 1994, when he left to found the venture capital firm Kingsbury Capital Partners. Kingbury’s investments include Aurora Biosciences, Amylin Pharmaceuticals, Phamis Software, Health Data Sciences, Senomyx, Sub-Q, TKT, Althea, and Digirad.
In San Diego, he was named Entrepreneur of the Year in 1995 and Corporate Director of the Year in 2001. Mr. Wollaeger earned a B.A. in Economics from Yale in 1966, served as an officer in the U.S. Navy for three years, and earned an MBA from The Stanford Graduate School of Business in 1971.

 

Linda Pinney

Asteres Inc.

Linda, Founder of Asteres Inc., was the CEO of The StartUp Lab, Inc., a venture development company serving venture capital firms and venture-backed companies. Previously she founded and was Chairman & CEO for DNA Dynamics, Inc., a top 10 finalist for San Diego’s most innovative new company of the year award. Linda was hired as the 13th employee of Pyxis Corporation and served as Vice President of Business Development. Linda successfully developed, patented and led Pyxis into new product offerings including SupplyStation, Pyxis Data System and PyxisStation. She also created and led the Alternate Site Division to $20 million in revenue in two years. Linda took Pyxis outside healthcare constructing a licensing and equity deal with a private company pursuing industry applications of Pyxis products. Pyxis enjoyed a successful IPO and was sold to Cardinal Health for close to $1 billion. Prior to Pyxis, Linda was in business development for Sharp HealthCare and Centinela Hospital. She has a Bachelor of Science in Genetics from U.C. Davis, and a Masters in Business & Healthcare Administration from U.S.C.